This article features a discussion on the management of rapid cycling bipolar disorder and the role of lithium, providing clinical insights for psychiatrists prescribing mood stabilizers.
Enveric Biosciences has secured a patent for psilocybin derivatives, marking a development in the intellectual property landscape for psychedelic therapeutics.
A study from Children’s Hospital Los Angeles investigates the utility of genetic testing to guide SSRI prescribing in pediatric patients, highlighting ongoing research into pharmacogenomics for antidepressant efficacy.
An open-label trial evaluates the efficacy and safety of a single dose of psilocybin for treating chronic suicidal ideation, providing early clinical data on this psychedelic intervention for high-risk psychiatric symptoms.
A post hoc analysis of clinical trials for once-monthly aripiprazole calculates NNT, NNH, and LHH metrics to quantify the benefit-risk profile for schizophrenia treatment.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from May 11 – May 13)
- Consider ordering pre-treatment structural MRI for patients with treatment-resistant depression to leverage machine learning models that can predict ketamine response and aid in treatment stratification.
- Utilize NNT, NNH, and LHH metrics when discussing the benefit-risk profile of once-monthly aripiprazole with patients to quantify the trade-offs of long-acting injectable antipsychotics.
- Monitor for potential pharmacokinetic interactions when prescribing lithium, specifically noting that high-dose vitamin C can alter lithium levels and requires careful management.
- Recognize that lithium's anti-suicidal effects are mechanistically linked to its modulation of specific brain signals associated with suicide risk, reinforcing its role in high-risk mood disorder management.
- Screen for insulin resistance in patients with bipolar disorder, as it is linked to gray matter loss and cognitive impairment, potentially indicating a benefit from metabolic interventions such as GLP-1 agonists.
- Apply consensus guidelines for initiating medications for opioid use disorder (MOUD) within hospital settings to ensure timely and standardized care for patients presenting with acute withdrawal or overdose risk.
- Consider the emerging evidence for psilocybin in treating chronic suicidal ideation in treatment-resistant depression, acknowledging that early open-label trials show promise for this high-risk population.
- Evaluate the potential for psilocybin-assisted therapy in patients with cocaine use disorder, as recent trials suggest it may significantly increase cocaine-free days compared to standard care.
- Be aware of rare but serious adverse events associated with psychiatric medications, including venous thromboembolism from antipsychotics and vasculitis from SSRIs, when monitoring long-term safety.
- Explore glutamatergic treatment avenues for PTSD, such as fluoxetine-potentiated dextromethorphan protocols, for patients who have not responded to traditional first-line therapies.
Clinical Pearl 3
An open-label trial of a single 25-mg dose of psilocybin for chronic suicidal ideation in patients with treatment-resistant depression provides early efficacy and safety data for this high-risk population.
Real-world data from Oregon's regulated psilocybin program show low acute adverse event rates and utilization patterns that inform the safety profile and equity considerations of psilocybin-assisted therapy.
This editorial summarizes case reports highlighting psilocybin's potential for OCD, lithium pharmacokinetics interactions with vitamin C, and adverse events including VTE from antipsychotics and vasculitis from SSRIs.
Drug Development 4
Response Pharmaceuticals will present clinical data on RDX-002, a potential treatment for antipsychotic-induced weight gain, at the 2026 APA Annual Meeting.
Alkermes' narcolepsy drug Lumryz achieved success in its Phase 3 study, reinforcing the clinical profile of this established treatment for narcolepsy.
A clinical trial at MD Anderson is investigating psilocybin-assisted therapy to address mental health challenges in cancer patients, highlighting the expanding research into psychedelic treatments for psychiatric comorbidities in oncology.
A clinical trial is evaluating psilocybin therapy for mental health issues associated with cancer, representing a psych-indication trial relevant to psychiatric pharmacology.
Mechanism of Action 3
Research identifies that lithium modulates specific brain signals associated with suicide risk, providing mechanistic insight into its anti-suicidal effects.
Research demonstrates that a single psilocybin experience produces long-lasting neural changes, providing mechanistic insight into the sustained effects of this psychedelic therapeutic.
This article explores the use of psilocybin for treating obsessive-compulsive disorder, providing insights into the mechanism of action and potential therapeutic applications of psychedelics in psychiatry.
Policy & Regulation 2
An executive order accelerating psychedelics research coincides with legislative or regulatory developments regarding psilocybin in New York, highlighting the evolving landscape of psychedelic-assisted therapy.
Robert F. Kennedy Jr. has expressed goals to reduce the overuse of antidepressant drugs in the United States, highlighting a policy and regulatory perspective on psychopharmacology prescribing practices.
Diagnosis & Treatment 3
This systematic review identifies key barriers (e.g., stigma, knowledge gaps) and facilitators (e.g., education, specialized care) for implementing deep brain stimulation in psychiatry, offering insights for improving clinical adoption of this neuromodulation therapy.
A machine learning model using pre-treatment structural MRI data can predict ketamine response in treatment-resistant depression with moderate accuracy, suggesting potential for biomarker-informed treatment stratification.
A four-patient case series reports rapid symptom improvement in trauma-related disorders using an oral protocol of fluoxetine-potentiated dextromethorphan with optional bupropion and piracetam, suggesting a potential glutamatergic treatment avenue for PTSD.
Substance Use 4
A consensus of 42 experts has established best practices for initiating medications for opioid use disorder (MOUD) within hospital settings.
Psilocybin is emerging as a potential therapeutic agent for smoking cessation, indicating a new application for this psychedelic compound in substance use disorder treatment.
A study suggests a single dose of psilocybin combined with psychotherapy significantly increases cocaine-free days in patients with cocaine use disorder.
Psilocybin shows promise for treating cocaine addiction, highlighting its potential as a novel pharmacotherapy for substance use disorders.
Neuroscience 1
New research links insulin resistance to gray matter loss and cognitive impairment in bipolar disorder, suggesting potential for metabolic interventions like GLP-1 agonists.